Results 21 to 30 of about 227,121 (132)

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

Pulmonary Circulation, 2021
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam, Ryan Avery, Isaac Goldberg, Courtney Makowski, Ravi Kalhan, Victoria Villaflor, Michael J. Cuttica   +6 more
doaj   +1 more source

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects

Frontiers in Oncology, 2021
Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to ...
Remy Thomas, Ghaneya Al-Khadairi, Ghaneya Al-Khadairi, Julie Decock, Julie Decock   +4 more
doaj   +1 more source

Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?

Asian Journal of Urology, 2016
Prostate cancers (PCa) have been reported to actively suppress antitumor immune responses by creating an immune-suppressive microenvironment. There is mounting evidence that PCas may undergo an ‘‘Epithelial Immune Cell-like Transition’’ (EIT) by ...
Dong Lin, Xinya Wang, Stephen Yiu Chuen Choi, Xinpei Ci, Xin Dong, Yuzhuo Wang   +5 more
doaj   +1 more source

Identification of the immune checkpoint signature of multiple myeloma using mass cytometry‐based single‐cell analysis

Clinical & Translational Immunology, 2020
Objectives New targets or strategies are needed to increase the success of immune checkpoint‐based immunotherapy for multiple myeloma (MM). However, immune checkpoint signals in MM microenvironment have not been fully elucidated. Here, we aimed to have a
Jinheng Wang, Yongjiang Zheng, Chenggong Tu, Hui Zhang, Karin Vanderkerken, Eline Menu, Jinbao Liu   +6 more
doaj   +1 more source

Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis

Frontiers in Cardiovascular Medicine, 2023
BackgroundImmune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early
Xin Zhang, Yi Gan, Haoshuai Zhu, Zhihao Liu, Xiaojing Yao, Chao Cheng, Zhenguo Liu, Chunhua Su, Jianyong Zou   +8 more
doaj   +1 more source

SnapShot: Immune Checkpoint Inhibitors

Cancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources

Nephrotoxicity of checkpoint inhibitors; a current challenge [PDF]

Journal of Nephropharmacology
Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system.
Samaneh Zandifar, Mahshid Imankhan, Padideh Daneii, Ali Azarpey, Leila Alem   +4 more
doaj   +1 more source

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Journal of Experimental & Clinical Cancer Research, 2021
Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies.
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime   +6 more
doaj   +1 more source

Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma

eLife
Radiation therapy is a primary treatment for hepatocellular carcinoma (HCC), but its effectiveness can be diminished by various factors. The over-expression of PD-L1 has been identified as a critical reason for radiotherapy resistance.
Tiesuo Zhao, Pengkun Wei, Congli Zhang, Shijie Zhou, Lirui Liang, Shuoshuo Guo, Zhinan Yin, Sichang Cheng, Zerui Gan, Yuanling Xia, Yongxi Zhang, Sheng Guo, Jiateng Zhong, Zishan Yang, Fei Tu, Qianqing Wang, Jin Bai, Feng Ren, Zhiwei Feng, Huijie Jia   +19 more
doaj   +1 more source

Gut microbiota shed new light on the management of immune‐related adverse events

Thoracic Cancer, 2022
Immunotherapy has dramatically revolutionized the therapeutic landscape for patients with cancer. Although immune checkpoint inhibitors are now accepted as effective anticancer therapies, they introduce a novel class of toxicity, termed immune‐related ...
Bei Tan, Yun‐xin Liu, Hao Tang, Dan Chen, Yan Xu, Min‐jiang Chen, Yue Li, Meng‐zhao Wang, Jia‐ming Qian   +8 more
doaj   +1 more source